Marshall Wace’s Unity Biotechnology UBX Stock Holding History

Marshall Wace’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-41,046	Closed	-$165K	–	3437
2022 Q3	$165K	Sell	41,046 -22,378	-35%	-$141K	﹤0.01%	3125
2022 Q2	$355K	Sell	63,424 -4,363	-6%	-$36.4K	﹤0.01%	2956
2022 Q1	$759K	Sell	67,787 -21,411	-24%	-$240K	﹤0.01%	2571
2021 Q4	$1.3M	Buy	89,198 +76,786	+619%	+$1.68M	﹤0.01%	2335
2021 Q3	$373K	Buy	12,412 +8,418	+211%	+$297K	﹤0.01%	2547
2021 Q2	$186K	Buy	+3,994	New	+$192K	﹤0.01%	2462
2020 Q2	–	Sell	-1,039	Closed	-$60K	–	1956
2020 Q1	$60K	Sell	1,039 -6,169	-86%	-$389K	﹤0.01%	1400
2019 Q4	$520K	Buy	7,208 +3,426	+91%	+$242K	﹤0.01%	1153
2019 Q3	$231K	Buy	+3,782	New	+$268K	﹤0.01%	1259

Other funds holding UBX

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace's UBX Position: Q4 2022 in Review

Marshall Wace sold out of Unity Biotechnology (UBX) in Q4 2022, closing a stake of 41,046 shares — an estimated $165K sold.

Marshall Wace first reported a position in UBX in Q3 2019 and held it in 9 quarters. The position peaked at $1.3M in Q4 2021. 54 funds tracked by Wall St. Rank hold UBX as of Q4 2022.

Marshall Wace reported no remaining Unity Biotechnology position as of Q4 2022 after selling out during the quarter.
Marshall Wace sold 41,046 Unity Biotechnology shares in Q4 2022, an estimated $165K.
Marshall Wace first reported a position in Unity Biotechnology in Q3 2019 and held it in 9 quarters.
Marshall Wace's Unity Biotechnology position peaked at $1.3M in Q4 2021.
54 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2022.

Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.